The Outsourcing in Clinical Trials Europe 2025 conference took place in Barcelona, Spain, April 29-30. The meeting provided an opportunity for clinicians, pharmaceutical company executives, trial software vendors, technology experts, and contract research and manufacturing organization executives to discuss the latest trends and challenges in the clinical trials space in Europe.
In this report, The analyst provides expert insights into key themes relevant to the clinical trials sector, with a focus on elements that drive successful operations in Europe. Through several panel discussions, presentations, roundtable talks, and demos over two days, experts shared insights on challenges in this sector and real-life examples on ways to overcome them.
Global clinical trends have evolved significantly in the post-pandemic era. According to the analyst, APAC led the total number of all clinical trials in 2024 with 14,562 trials, followed by North America, Europe, the Middle East and Africa, and South and Central America. Additionally, APAC had the highest proportion of Phase IV trials, followed by Europe. Moreover, China-based companies represented 30% of global clinical-stage development, with drugs in various phases, ranging from Phase 0 to NDA/BLA filing. As per a the analyst analysis of trials over the last decade, China has surpassed the US for the total number of clinical trials, including active (ongoing and planned) trials
In this report, The analyst provides expert insights into key themes relevant to the clinical trials sector, with a focus on elements that drive successful operations in Europe. Through several panel discussions, presentations, roundtable talks, and demos over two days, experts shared insights on challenges in this sector and real-life examples on ways to overcome them.
Global clinical trends have evolved significantly in the post-pandemic era. According to the analyst, APAC led the total number of all clinical trials in 2024 with 14,562 trials, followed by North America, Europe, the Middle East and Africa, and South and Central America. Additionally, APAC had the highest proportion of Phase IV trials, followed by Europe. Moreover, China-based companies represented 30% of global clinical-stage development, with drugs in various phases, ranging from Phase 0 to NDA/BLA filing. As per a the analyst analysis of trials over the last decade, China has surpassed the US for the total number of clinical trials, including active (ongoing and planned) trials
Scope
- Chief among the regulatory themes to explore for the clinical trials industry was the impact of the Accelerating Clinical Trials (ACT) EU initiative, which supports the implementation of the Clinical Trials Regulation (CTR) and adoption of the Clinical Trials Information System (CTIS).
- In this report, experts share insights on the following key trends:
- Strategies for building resilience in clinical trials
- Experts discuss the rollout of the ACT EU, successful partnerships between pharmaceutical companies and vendors, and innovative trial designs.
- AI in clinical trials
- The secrets to successful outsourcing partnerships
- Ways to achieve patient-centricity
- Clinical trial rescues
Reasons to Buy
- Gain insights on ways to understand regulation surrounding clinical trials in Europe, adoption trends in digital health for clinical trials, sponsor-CRO partner relationship trends, and more
Table of Contents
- Executive Summary
- Developing resilient strategies to overcome challenges in clinical research in Europe
- Charting success through uncertainty in AI clinical trial implementation
- Small and mid-sized sponsors demand smart and reliable partnerships
- Patient-centricity and effective designs drive clinical trial success
- Clinical trial rescue: how to achieve a seamless study transition
- About the Authors
- Further Reading
- The analyst reports
- About the Analyst
- Contact the Publisher
